Severe early natalizumab-associated PML in MS: Effective control of PML-IRIS with maraviroc


Case report. A 55-year-old Caucasian HIV-negative man diagnosed with relapsing-remitting MS in 2013 and an Expanded Disability Status Scale (EDSS) score of 2.0 had received 20 infusions of natalizumab over 21 months without a history of prior immunotherapy. John Cunningham–virus (JCV) antibodies were positive at the initiation of treatment (index: 0.4… (More)
DOI: 10.1212/NXI.0000000000000323